多药耐药多态性对环孢素急性肝毒性作用的影响

目的 探讨多药耐药(MDR)多态性对环孢素急性肝毒性作用的影响.方法 采用聚合酶链反应(PCR)和限制性内切片段多态性(RFLP)方法 对187例肾移植患者进行MDR外显子26(exon 26)基因分型;并以外显子26基因型分组,观察不同MDR基因型患者环孢素急性肝毒性的发生率.结果 187例,MDR exon26基因型分为CC、CT和TT.各基因型所占的比例分别为29.4%(55/187),40.1%(75/187)和30.5%(57/187).在环孢素使用剂量相同的情况下,CT/TT基因型的患者肝毒性的发生率明显高于CC基因型(35.9%/31.6%∶18.3%,P＜0.05);不同基因型分组之间,发生环孢素肝毒性的平均血药浓度也有较大的差别(CC:CT/TT:432.5±30.0∶338.6±26.8/315.3±25.6,P＜0.05).结论 MDR多态性是影响环孢素急性肝毒性作用的重要因素之一.

Abstract：

Objective To investigate the influence of MDR polymorphism on CsA-associated hepatotoxicity. Methods PCR/RFLP was used to analyze the genotypes of MDR exon26 in 187 recipients. CsA-associated hepatotoxicity was evaluated among groups being classified according to the genotypes. Results MDR exon26 takes 3 genotypes:CC,CT and TT, in the following ratio: 29.4%(55/187), 40.1%(75/187), 30. 5%(57/187). Among the same range of whole blood CsA concentration, incidence of CsA-associated hepatotoxicity is markedly higher in the CT/TT group than that in in patients with CsA-associated hepatotoxicity between the CC group and the CT/TT group is signifiimportant role in the development of CsA-associated hepatotoxicity.

Influence of multidrug resistance polymorphism on CsA-associated hepatotoxicity

Objective To investigate the influence of MDR polymorphism on CsA-associated hepatotoxicity. Methods PCR/RFLP was used to analyze the genotypes of MDR exon26 in 187 recipients. CsA-associated hepatotoxicity was evaluated among groups being classified according to the genotypes. Results MDR exon26 takes 3 genotypes:CC,CT and TT, in the following ratio: 29.4%(55/187), 40.1%(75/187), 30. 5%(57/187). Among the same range of whole blood CsA concentration, incidence of CsA-associated hepatotoxicity is markedly higher in the CT/TT group than that in in patients with CsA-associated hepatotoxicity between the CC group and the CT/TT group is signifiimportant role in the development of CsA-associated hepatotoxicity.